Learn the GLP-1 weight loss category.

The headline price is rarely the real price. Here is the anatomy of an honest monthly bill, and the four hidden cost mechanisms used by every major program.

Compounded GLP-1s are the same molecule as Wegovy and Ozempic but a fundamentally different regulatory product. Here is the truth on safety, sourcing, and why the cheap-tier era is ending.

Auto-renewal, free-trial conversion, non-refundable upfront, lock-in commitments, phone-only cancel, medication forfeit, dispute waiver. The full list of legal mechanisms programs use to keep your money.

Hims says no lock-in. WeightWatchers says 12 months. Found says 6-month non-refundable. The phrase has at least four real meanings, and the difference is thousands of dollars.

Novo Nordisk's exclusivity on semaglutide expires in stages from 2026. Here is the realistic timeline, the price implications, and which programs will move first.

Most commercial insurance now covers semaglutide and tirzepatide for obesity, but coverage is uneven. Here is how to figure out what you actually pay before you commit to a program.

Wegovy at 14.9% mean weight loss. Zepbound at 22.5%. Saxenda at 7.4%. The numbers behind every weight-loss program's marketing copy, and what they hide.

Nausea is the headline. The full picture from registration trials includes diarrhea, fatigue, gallstones, and a few rare-but-serious events worth knowing about before you start.

Standard titration is one dose level every four weeks. The published schedule is a default, not a law. Here is what to do when the standard schedule does not fit your tolerance.

Most patients hit at least one weight loss stall on a GLP-1. Some are real, some are measurement noise, some signal a need to escalate. Here is how to tell which kind you are dealing with.

The data say yes for most patients. The economics, the side effects, and the long-term safety record are all evolving. Here is the honest state of play in 2026.

Ozempic and Wegovy are the same molecule. Mounjaro and Zepbound are the same molecule. The differences are in dose, indication, insurance coverage, and what your prescription actually says.

Medicaid coverage for Wegovy, Zepbound, and other GLP-1s varies wildly by state. The federal program does not require coverage for weight loss drugs, so each state's preferred drug list (PDL) decides. Here's the framework for finding out what your state covers and the broad pattern in 2026.